BioCentury
ARTICLE | Emerging Company Profile

Quenching the flames of inflammatory cell death

With a $50M round, Quench is developing first-in-class gasdermin D inhibitors to treat inflammatory diseases.

January 28, 2020 12:21 AM UTC
Updated on Feb 1, 2020 at 2:26 AM UTC

Emerging from stealth Monday with a $50 million A round, Quench Bio is targeting the nexus of inflammatory cell death.

RA Capital led the round with participation from new investor AbbVie Ventures. Atlas Venture and Arix Bioscience plc (LSE:ARIX), which co-founded and seeded Quench Bio Inc., also participated...